These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 29199201)

  • 1. Effects of a Dipeptidyl Peptidase 4 Inhibitor Sitagliptin on Glycemic Control and Lipoprotein Metabolism in Patients with Type 2 Diabetes Mellitus (GLORIA Trial).
    Masuda D; Kobayashi T; Sairyou M; Hanada H; Ohama T; Koseki M; Nishida M; Maeda N; Kihara S; Minami T; Yanagi K; Sakata Y; Yamashita S
    J Atheroscler Thromb; 2018 Jun; 25(6):512-520. PubMed ID: 29199201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short and Long Term Effects of a DPP-4 Inhibitor Versus Bedtime NPH Insulin as ADD-ON Therapy in Patients with Type 2 Diabetes.
    da Silva GM; Nogueira KC; Fukui RT; Correia MR; Dos Santos RF; da Silva ME
    Curr Pharm Des; 2016; 22(44):6716-6721. PubMed ID: 27928958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sitagliptin improves plasma apolipoprotein profile in type 2 diabetes: A randomized clinical trial of sitagliptin effect on lipid and glucose metabolism (SLIM) study.
    Tanimura-Inagaki K; Nagao M; Harada T; Sugihara H; Moritani S; Sasaki J; Kono S; Oikawa S;
    Diabetes Res Clin Pract; 2020 Apr; 162():108119. PubMed ID: 32194219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining the G-protein-coupled receptor 40 agonist fasiglifam with sitagliptin improves glycaemic control in patients with type 2 diabetes with or without metformin: A randomized, 12-week trial.
    Peng XV; Marcinak JF; Raanan MG; Cao C
    Diabetes Obes Metab; 2017 Aug; 19(8):1127-1134. PubMed ID: 28239939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Anagliptin and Sitagliptin on Low-Density Lipoprotein Cholesterol in Type 2 Diabetic Patients with Dyslipidemia and Cardiovascular Risk: Rationale and Study Design of the REASON Trial.
    Ueda S; Shimabukuro M; Arasaki O; Node K; Nomiyama T; Morimoto T
    Cardiovasc Drugs Ther; 2018 Feb; 32(1):73-80. PubMed ID: 29435776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy.
    Furuhashi M; Sakuma I; Morimoto T; Higashiura Y; Sakai A; Matsumoto M; Sakuma M; Shimabukuro M; Nomiyama T; Arasaki O; Node K; Ueda S
    J Atheroscler Thromb; 2022 Jan; 29(1):24-37. PubMed ID: 33342939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of sitagliptin therapy on triglyceride-rich lipoprotein kinetics in patients with type 2 diabetes.
    Tremblay AJ; Lamarche B; Kelly I; Charest A; Lépine MC; Droit A; Couture P
    Diabetes Obes Metab; 2014 Dec; 16(12):1223-9. PubMed ID: 25059982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes.
    Tremblay AJ; Lamarche B; Deacon CF; Weisnagel SJ; Couture P
    Diabetes Obes Metab; 2011 Apr; 13(4):366-73. PubMed ID: 21226820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin.
    Hayashi T; Fukui T; Nakanishi N; Yamamoto S; Tomoyasu M; Osamura A; Ohara M; Yamamoto T; Ito Y; Hirano T
    Cardiovasc Diabetol; 2017 Jan; 16(1):8. PubMed ID: 28086872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial.
    Oe H; Nakamura K; Kihara H; Shimada K; Fukuda S; Takagi T; Miyoshi T; Hirata K; Yoshikawa J; Ito H;
    Cardiovasc Diabetol; 2015 Jun; 14():83. PubMed ID: 26084668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study.
    Yamada H; Tanaka A; Kusunose K; Amano R; Matsuhisa M; Daida H; Ito M; Tsutsui H; Nanasato M; Kamiya H; Bando YK; Odawara M; Yoshida H; Murohara T; Sata M; Node K;
    Cardiovasc Diabetol; 2017 May; 16(1):63. PubMed ID: 28490337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Add-on treatment with mitiglinide improves residual postprandial hyperglycemia in type 2 diabetic patients receiving the combination therapy with insulin glargine and sitagliptin.
    Murakami T; Nambu T; Kato T; Matsuda Y; Yonemitsu S; Muro S; Oki S
    Tohoku J Exp Med; 2015 Apr; 235(4):255-60. PubMed ID: 25810423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sitagliptin for prevention of stress hyperglycemia in patients without diabetes undergoing general surgery: A pilot randomized study.
    Fayfman M; Davis G; Duggan EW; Urrutia M; Chachkhiani D; Schindler J; Pasquel FJ; Galindo RJ; Vellanki P; Reyes-Umpierrez D; Wang H; Umpierrez GE
    J Diabetes Complications; 2018 Dec; 32(12):1091-1096. PubMed ID: 30253968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Glycemic Control on Chylomicron Metabolism and Correlation between Postprandial Metabolism of Plasma Glucose and Chylomicron in Patients with Type 2 Diabetes Treated with Basal-bolus Insulin Therapy with or without Vildagliptin.
    Okajima F; Emoto N; Kato K; Sugihara H
    J Atheroscler Thromb; 2017 Feb; 24(2):157-168. PubMed ID: 27397060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus: A focus on hypoglycemia.
    Fukuda M; Doi K; Sugawara M; Mochizuki K
    J Diabetes Investig; 2019 Mar; 10(2):383-391. PubMed ID: 30136435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial.
    Chihara A; Tanaka A; Morimoto T; Sakuma M; Shimabukuro M; Nomiyama T; Arasaki O; Ueda S; Node K
    Cardiovasc Diabetol; 2019 Nov; 18(1):158. PubMed ID: 31733647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Canagliflozin Compared With Sitagliptin on Serum Lipids in Patients with Type 2 Diabetes Mellitus and Heart Failure with Reduced Ejection Fraction: A Post-Hoc Analysis of the CANA-HF Study.
    Dixon DL; Billingsley HE; Canada JM; Trankle CR; Kadariya D; Cooke R; Hart L; Van Tassell B; Abbate A; Carbone S
    J Cardiovasc Pharmacol; 2021 Sep; 78(3):407-410. PubMed ID: 34132690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dipeptidyl peptidase-4 inhibitor sitagliptin improves pancreatic β-cell function in hypertensive diabetic patients treated with angiotensin receptor blockers.
    Fukui K; Kawahito H; Wakana N; Kikai M; Terada K; Yamamoto K; Irie D; Kato T; Miyagawa S; Yamada H
    J Renin Angiotensin Aldosterone Syst; 2015 Dec; 16(4):1001-9. PubMed ID: 26195265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between urinary albumin excretion and low-density lipoprotein heterogeneity following treatment of type 2 diabetes patients with the dipeptidyl peptidase-4 inhibitor, vildagliptin: a pilot study.
    Tani S; Nagao K; Hirayama A
    Am J Cardiovasc Drugs; 2013 Dec; 13(6):443-50. PubMed ID: 23990203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.